Table 1 The causes and consequences of mitochondrial dysfunction in different cancer
Gene | Year | Cancer type | Causes of mitochondrial dysfunction | Consequences | References |
|---|---|---|---|---|---|
DRP1 | 2022 | Pituitary adenomas | Upregulation | Inhibit the tumor growth | [60] |
DRP1 | 2022 | Esophageal squamous cell carcinoma | Upregulation | Trigger autophagy and promote ESCC progression | [61] |
DRP1 | 2022 | Hepatocellular carcinoma | Upregulation | Promote tumor metastasis | [62] |
DRP1 | 2022 | Colon cancer | Upregulation | Promote fatty acids-induced metabolic reprograming | [63] |
DRP1 | 2022 | Head and neck cancer | Upregulation | Promote tumor growth and metastasis and induce glycolysis | [64] |
DRP1 | 2021 | Pancreatic cancer | Upregulation | Maintain stemness-related features, such as self-renewal, tumorigenicity, and invasiveness | [65] |
DRP1 | 2021 | Colon cancer | Upregulation | Promote colon tumorigenesis | [66] |
DRP1 | 2021 | Cancer stem cells | Upregulation | Promote stemness and chemoresistance | [67] |
DRP1 | 2021 | Colorectal cancer | Upregulation | Promote tumor progression and metabolic reprogramming | [68] |
DRP1 | 2021 | Hepatocellular carcinoma | Downregulation | Inhibit the proliferation and migration | [69] |
DRP1 | 2020 | Lung cancer | Upregulation | Contribute to baicalein-induced apoptosis and autophagy | [70] |
DRP1 | 2020 | Prostate cancer | Upregulation | Regulate mitochondrial metabolic reprogramming | [71] |
DRP1 | 2020 | Ovarian cancer | Upregulation | Promote pancreatic cancer growth and metastasis | [72] |
DRP1 | 2020 | Pancreatic cancer | Upregulation | Promote pancreatic cancer growth and metastasis | [73] |
DRP1 | 2020 | Hepatocellular carcinoma | Downregulation | Promote mitophagy | [74] |
DRP1 | 2020 | Uterine | Upregulation | Promote metastasis | [75] |
DRP1 | 2020 | Ovarian cancer; colorectal cancer | Upregulation | Promote proliferation | [76] |
DRP1 | 2020 | Lung cancer | Upregulation | Promote proliferation and metabolic reprogramming | [77] |
DRP1 | 2020 | Renal cell carcinomas | Upregulation | Promote migration and invasion | [78] |
DRP1 | 2020 | Breast cancer | Upregulation | Positively correlate with infiltration levels of immune system | [79] |
DRP1 | 2018 | Breast cancer | Upregulation | Contribute to IR-783-induced apoptosis | [80] |
FIS1 | 2022 | Gastric adenocarcinoma | Upregulation | Promote metastasis | [81] |
FIS1 | 2021 | Hepatocellular carcinoma | Phosphorylation | Promote metastasis | [81] |
FIS1 | 2018 | Esophageal cancer | Downregulation | Decrease the mitochondrial membrane potential | [82] |
MFN1 | 2022 | Hepatocellular carcinoma | Downregulation | Inhibit reprogramming cellular metabolism | [83] |
MFN1 | 2022 | Liver cancer | Downregulation | Promote aerobic glycolysis and proliferation | [84] |
MFN1 | 2020 | Hepatocellular carcinoma | Downregulation | Promote cell proliferation, invasion and migration capacity by modulating metabolic reprogramming | [85] |
MFN2 | 2022 | Ovarian cancer | Upregulation | Promote autophagy, reduce ROS, and suppress OC progression | [86] |
MFN2 | 2021 | Thyroid cancer | Upregulation | Inhibit cell migration and invasion | [87] |
MFN2 | 2021 | Pancreatic cancer | Upregulation | Inhibit cell growth while promoting the formation of apoptotic bodies | [88] |
MFN2 | 2021 | Cervical cancer | Downregulation | Reduce the proliferation, colony formation ability, migration, and in vivo tumorigenesis | [89] |
MFN2 | 2018 | Pancreatic cancer | Downregulation | Induce apoptosis, metabolism disorder and migration impairment | [90] |
MFN2 | 2021 | Lung cancer | Phosphorylation | promote cell proliferation | [91] |
NRF1 | 2021 | Renal cell carcinoma | Upregulation | Promote cell proliferation | [92] |
NRF1 | 2020 | Liver cancer | Downregulation | Promote proliferation, invasion and metastasis | [93] |
NRF1 | 2018 | Insulinoma | Downregulation | Acquire aggressiveness and chemoresistance | [94] |
NRF2 | 2021 | Head and neck cancer | Upregulation | Promote proliferation and metabolic reprogramming | [95] |
OPA1 | 2022 | Breast cancer | Downregulation | Reduce proliferation, migration, and invasion | [53] |
OPA1 | 2022 | Pancreatic ductal adenocarcinoma | Upregulation | Acquire stemness capacity | [96] |
OPA1 | 2020 | Liver cancer | Upregulation | Alter metabolism and promote tumor cell growth | [54] |
PGC-1α | 2021 | Pancreatic cancer | Upregulation | Promote metabolic reprogramming and stemness features | [97] |
PGC-1α | 2020 | Melanoma | Upregulation | Promote metastasis | [98] |
PGC-1α | 2021 | Hepatocellular carcinoma | Upregulation | Inhibit cell proliferation and induce apoptosis | [99] |
PGC-1α | 2021 | Pancreatic cancer | Upregulation | Promote growth and invasion | [100] |
PGC-1α | 2020 | Breast cancer | Upregulation | Inhibit glycolytic metabolism and proliferation | [101] |
PINK1 | 2021 | Breast cancer | Upregulation | Trigger PINK1/Parkin-mediated mitophagy and induce mitochondrial apoptosis | [102] |
PINK1 | 2021 | Colon tumor | Upregulation | Suppress colon tumor growth | [103] |
PINK1 | 2021 | Bladder cancer | Downregulation | Promote bladder tumor cell growth | [104] |
PINK1 | 2019 | Lung cancer | Downregulation | Reduce cancer cell proliferation, increase cell death, reduce ATP production, inhibit mitophagy | [105] |
SIRT1 | 2022 | Ovarian cancer | Upregulation | Increase mitochondrial activity | [106] |
SIRT1 | 2019 | Prostate cancer | Upregulation | Promote metastasis | [107] |
SIRT1 | 2019 | Liver cancer | Upregulation | Enhance the metabolic flexibility of liver cancer stem cells | [108] |
SIRT1 | 2019 | Rectal cancer | Upregulation | Inhibit growth | [109] |
TFAM | 2022 | Lung cancer | Downregulation | Inhibit growth | [110] |
TFAM | 2021 | Colorectal cancer | Upregulation | Promote the proliferation | [111] |
TFAM | 2021 | Head and neck tumorigenesis | Downregulation | Enhance cell growth, motility and chemoresistance | [58] |
TFAM | 2021 | Liver cancer | Downregulation | Promote metastasis | [112] |
TFAM | 2021 | Breast cancer | Upregulation | Promote breast cancer development and metastasis | [113] |
TFAM | 2020 | Sarcoma | Downregulation | Inhibit cell proliferation | [114] |